A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.
Completed · Phase 1
Conditions studied: Autoimmune and Chronic Inflammatory Diseases
In brief
The purpose of this study is to support the development of remibrutinib dosing recommendations for patients with impaired renal function.
Key facts
- Study ID
- NCT07032272
- Run by
- Novartis Pharmaceuticals
- People needed
- 16
- Starts
- 2025-07-23
- Expected to finish
- 2025-10-14
- Last updated by the study team
- 2026-03-30
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.
Where it is running
- Clinical Pharmacology of Miami LLC — Miami, Florida, United States
- Panax Clinical Research — Miami Lakes, Florida, United States
- Orlando Clinical Research Center — Orlando, Florida, United States
- Genesis Clinical Research — Tampa, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.